Research
Market
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% (5 mL and 10 mL).
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb Incorporated. Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3%, is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Alembic was granted a Competitive Generic Therapy (CGT) designation for this application. With this approval, Alembic is eligible for 180 days of CGT exclusivity upon commercialization.
Associated Alcohols & Breweries has launched its premium product portfolio in the State of Jharkhand. The portfolio includes Nicobar Indian Dry Gin, Titanium Triple Distilled Vodka, and Hillfort and Central Province in the whiskey category. This strategic expansion underscores the Company's continued commitment to delivering exceptional craftsmanship and curated spirits across new markets.
Commenting on this development, Prasann Kumar Kedia, Managing Director, stated: “We are pleased to introduce our premium portfolio to the Jharkhand market, a region that presents strong growth potential for the Company. The launch of Nicobar Indian Dry Gin, Titanium Triple Distilled Vodka, and our premium whiskey brands—Hillfort and Central Province—marks another significant step in our strategy to expand our national footprint. We remain committed to offering high-quality, well-crafted spirits that cater to evolving consumer preferences. Jharkhand represents a promising opportunity, and we are confident that our premium offerings will resonate well with discerning customers in the state.”
Aurionpro announced AurionAI, a domain-centric Enterprise AI platform for banking and financial services that aims to power the world's fastest, most trustworthy, and deepest banking AI engine. Positioned to cut through AI hype with demonstrable depth and maturity, AurionAI debuted at Aurionpro's flagship event, Enterprise AI Unleashed.
AurionAI introduces a category Aurionpro calls domain-led Enterprise AI for BFSI, unifying a cutting-edge horizontal AI engineering platform with deep banking domain intelligence. Unlike generic enterprise AI platforms or standalone banking products, AurionAI is purpose built for regulated financial institutions, with banking ontologies, controls, and workflows embedded by design.
Combining banking-specific intelligence, engineering governance, and deep operational roots, the platform positions Aurionpro as a trusted enterprise AI technology provider, enabling banks to build their own intelligence and deploy AI agents with confidence.